3 completed. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
Follow Peripheral Primitive Neuroectodermal Tumor: new trials by email Literature Review of Peripheral Primitive Neuroectodermal Tumor trials Research Report on Peripheral Primitive Neuroectodermal Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) Laboratory Biomarker Analysis, Vemurafenib - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 4 | 2017-11-08 | 2025-01-27 |
| Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma topotecan hydrochloride, vincristine sulfate, cyclophosphamide - Ewing Sarcoma of Bone, Extraosseous Ewing Sarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 7 | 2008-02-01 | 2014-09-02 |
| Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors trabectedin, pharmacological study - Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Rhabdomyosarcoma | Phase 2 | Completed | Children's Oncology Group | 50 | 2008-01-01 | 2018-09-14 |
Neuroectodermal Tumors, Primitive, Peripheral (3) · Sarcoma, Ewing (2) · Central Nervous System Neoplasms (1) · Ependymoma (1) · Glioma (1) · Hepatoblastoma (1) · Histiocytosis, Langerhans-Cell (1) · Lymphoma, Non-Hodgkin (1) · Neuroblastoma (1) · Osteosarcoma (1) · Rhabdoid Tumor (1) · Rhabdomyosarcoma (1) · Sarcoma (1) · Wilms Tumor (1)
Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms, Germ Cell and Embryonal (3) · Neoplasms, Glandular and Epithelial (3) · Neoplasms, Nerve Tissue (3) · Neoplasms, Neuroepithelial (3) · Neuroectodermal Tumors (3) · Neuroectodermal Tumors, Primitive (3) · Neoplasms, Bone Tissue (2) · Neoplasms, Connective Tissue (2) · Neoplasms, Connective and Soft Tissue (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genetic Diseases, Inborn (1)
Bevacizumab (1) · Cyclophosphamide (1) · Topotecan (1) · Trabectedin (1) · Vemurafenib (1) · Vincristine (1) · trioctyl phosphine oxide (1)
National Cancer Institute (NCI) (2) · Children's Oncology Group (1)
United States (3) · Canada (1) · Puerto Rico (1)
AeRang Kim (1) · Patrick Leavey, MD (1) · Sylvain Baruchel, MD (1)
PMID 22088484, PMID 31401903, PMID 38873934
U10CA098543 (2), U10CA180886 (1)